US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
AUPN741696A0
(en)
*
|
1996-01-05 |
1996-01-25 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids ii
|
FR2756491B1
(fr)
*
|
1996-11-29 |
1999-01-08 |
Rhone Poulenc Rorer Sa |
Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
|
US7097854B2
(en)
|
1996-09-12 |
2006-08-29 |
Medigene Oncology Gmbh |
Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds
|
DE19637043A1
(de)
*
|
1996-09-12 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
|
FR2754272B1
(fr)
*
|
1996-10-08 |
1998-11-13 |
Rhone Poulenc Rorer Sa |
Procede de preparation de compositions pour le transfert d'acides nucleiques
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
IL132323A0
(en)
|
1997-04-28 |
2001-03-19 |
Rhone Poulenc Rorer Sa |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
FR2763943B1
(fr)
*
|
1997-05-28 |
1999-07-09 |
Rhone Poulenc Rorer Sa |
Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
IL137247A0
(en)
|
1998-01-30 |
2001-07-24 |
Aventis Pharma Sa |
Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
|
FR2777017B1
(fr)
*
|
1998-04-02 |
2002-08-23 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
|
HUP0102455A3
(en)
*
|
1998-04-02 |
2003-09-29 |
Aventis Pharma Sa |
Novel nucleic acid transfer agents, compositions containing same and uses
|
US6583301B1
(en)
|
1998-04-08 |
2003-06-24 |
Celltech R & D Limited |
Lipids
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
ATE368027T1
(de)
*
|
1999-04-26 |
2007-08-15 |
Celltech R&D Ltd |
Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
AU1556701A
(en)
*
|
1999-12-02 |
2001-06-12 |
Tomohiko Ohwada |
Reagents for gene transfer
|
EP1276500B1
(de)
|
2000-03-13 |
2011-06-08 |
Cornell Research Foundation, Inc. |
Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
WO2001079299A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
KR100373845B1
(ko)
*
|
2000-09-21 |
2003-02-26 |
굿젠 주식회사 |
유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
|
KR100373844B1
(ko)
*
|
2000-09-21 |
2003-02-26 |
굿젠 주식회사 |
유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US20020091242A1
(en)
|
2000-10-11 |
2002-07-11 |
Michel Bessodes |
Acid-sensitive compounds, their preparation and uses
|
DE60144198D1
(de)
|
2000-12-28 |
2011-04-21 |
Wyeth Llc |
Rekombinantes schutzprotein aus streptococcus pneumoniae
|
EP1572862B1
(de)
|
2001-02-20 |
2012-08-01 |
Intrexon Corporation |
Chimäre retinoid-x-rezeptoren und ihre verwendung in einem neuen induzierbaren genexpressionssystem auf ecdysonrezeptor-basis
|
EP1373470B1
(de)
|
2001-02-20 |
2013-04-24 |
Intrexon Corporation |
Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionssystem auf basis eines nukleären rezeptors
|
DK1534738T3
(da)
|
2001-02-20 |
2012-10-01 |
Intrexon Corp |
Nye substitutionsmutantreceptorer og anvendelse heraf i et inducérbart genekpressionssystem på basis af en nuklear receptor
|
MXPA03007493A
(es)
|
2001-02-20 |
2004-10-15 |
Rheogene Holdings Inc |
Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
|
CN1610556A
(zh)
|
2001-03-02 |
2005-04-27 |
洛克菲勒大学 |
保留天然变应原的免疫原性并具减弱的变应原性的重组杂合变应原构建体
|
CA2930389A1
(en)
|
2001-09-26 |
2003-04-03 |
Intrexon Corporation |
Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
CA2459827C
(en)
|
2001-09-26 |
2013-09-03 |
Subba Reddy Palli |
Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
EP1479985B1
(de)
|
2002-01-17 |
2017-06-14 |
Alfa Laval Corporate AB |
Getauchter Verdampfer umfassend einen Plattenwärmetauscher und ein zylindrisches Gehäuse in dem der Plattenwärmetauscher angeordnet ist
|
EP2316921B1
(de)
|
2002-05-24 |
2014-05-14 |
Merck Sharp & Dohme Corp. |
Humaner neutraliserender Anti-IGFR Antikörper
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7304161B2
(en)
*
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
DK1745295T3
(da)
|
2004-04-20 |
2011-01-31 |
Galapagos Nv |
Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
|
WO2005103716A2
(en)
|
2004-04-27 |
2005-11-03 |
Galapagos N.V. |
Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
EP2256198A1
(de)
|
2004-06-14 |
2010-12-01 |
Galapagos N.V. |
Identifizierungsverfahren und Verbindungen für die Behandlung degenerativer und entzündlicher Erkrankungen
|
US20070004658A1
(en)
|
2004-06-21 |
2007-01-04 |
Nick Vandeghinste |
Method and means for treatment of osteoarthritis
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
WO2006020071A2
(en)
|
2004-07-16 |
2006-02-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Vaccines against aids comprising cmv/r-nucleic acid constructs
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
WO2007005898A2
(en)
|
2005-07-05 |
2007-01-11 |
Cornell Research Foundation, Inc. |
Blocking leukocyte emigration and inflammation by interfering with cd99l2
|
WO2007028147A2
(en)
|
2005-09-01 |
2007-03-08 |
Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin |
Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
|
CN101495633B
(zh)
|
2006-07-28 |
2015-01-07 |
塞诺菲-安万特股份有限公司 |
用于治疗肿瘤的组合物和方法
|
CN101588816B
(zh)
|
2006-10-19 |
2013-06-19 |
Csl有限公司 |
白介素-13受体α1的高亲和性抗体拮抗物
|
CA2666682C
(en)
|
2006-10-19 |
2014-07-08 |
Merck & Co., Inc. |
Anti-il-13r.alpha.1 antibodies and their uses thereof
|
AU2007337897A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Imuthes Limited |
Lipids and their use as non-viral delivery vehicle
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
CA2689137C
(en)
|
2007-05-29 |
2017-05-02 |
Intrexon Corporation |
Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
EP2565649B1
(de)
|
2007-06-20 |
2015-04-15 |
Galapagos N.V. |
Molekulare Targets und Verbindungen sowie Verfahren zu ihrer Identifizierung für die Behandlung von degenerativen Knochen- und Gelenkserkrankungen
|
US20090069266A1
(en)
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
AU2008289461A1
(en)
|
2007-08-23 |
2009-02-26 |
Intrexon Corporation |
Methods and compositions for diagnosing disease
|
NZ583992A
(en)
*
|
2007-09-17 |
2012-11-30 |
Rohm & Haas |
A gene expression system for controllable expression of ethylene response in a plant
|
EP2205249B1
(de)
|
2007-09-28 |
2018-11-07 |
Intrexon Corporation |
Therapeutische genschalterkonstrukte und bioreaktoren zur expression biotherapeutischer moleküle und ihre verwendung
|
HUE035406T2
(en)
|
2007-10-08 |
2018-05-02 |
Intrexon Corp |
Engineered dendritic cells and uses for the treatment of cancer
|
WO2010026537A1
(en)
|
2008-09-05 |
2010-03-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Novel multimodular assembly useful for intracellular delivery
|
EP2352828B1
(de)
|
2008-09-11 |
2015-02-25 |
Galapagos N.V. |
Verfahren zur identifizierung von verbindungen zur erhöhung der aktivität von cf-assoziertem mutiertem cystic fibrosis transmembrane conductance regulator (cftr)
|
KR20110081282A
(ko)
|
2008-11-05 |
2011-07-13 |
와이어쓰 엘엘씨 |
베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
EP2398480A1
(de)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
|
JP2012517822A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
EP2398481A2
(de)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
US8663930B2
(en)
|
2009-04-01 |
2014-03-04 |
Galapagos Nv |
Methods and means for treatment of osteoarthritis
|
WO2010120374A2
(en)
|
2009-04-17 |
2010-10-21 |
New York University |
Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011116351A2
(en)
|
2010-03-19 |
2011-09-22 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
CN107519499A
(zh)
|
2010-03-23 |
2017-12-29 |
英特瑞克斯顿股份有限公司 |
条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用
|
KR101817450B1
(ko)
|
2010-08-23 |
2018-01-11 |
와이어쓰 엘엘씨 |
네이세리아 메닌기티디스 rLP2086 항원의 안정한 제제
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
WO2012076715A1
(en)
|
2010-12-09 |
2012-06-14 |
Institut Pasteur |
Mgmt-based method for obtaining high yield of recombinant protein expression
|
EP2492279A1
(de)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
|
JP6189754B2
(ja)
|
2011-03-04 |
2017-08-30 |
イントレキソン コーポレーション |
タンパク質を条件的に発現するベクター
|
WO2012135696A2
(en)
|
2011-04-01 |
2012-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
EP2546358A1
(de)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
|
CA2849267A1
(en)
|
2011-09-20 |
2013-03-28 |
The University Of North Carolina At Chapel Hill |
Regulation of sodium channels by plunc proteins
|
WO2013053765A1
(en)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
MX349562B
(es)
|
2011-12-09 |
2017-08-02 |
Pasteur Institut |
Ensayo de inmuno deteccion multiplex.
|
WO2013103401A1
(en)
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
CZ201220A3
(cs)
*
|
2012-01-13 |
2013-07-17 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Lipopolyaminy sperminového typu pro konstrukci liposomálních transfekcních systému
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
PE20142115A1
(es)
|
2012-03-09 |
2014-12-17 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas
|
EP2698377A1
(de)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
US20160003808A1
(en)
|
2013-03-14 |
2016-01-07 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
US9952202B2
(en)
|
2013-03-14 |
2018-04-24 |
Galapagos Nv |
Methods of identifying compounds for the treatment of fibrosis by using S1PR5
|
EP2972322B1
(de)
|
2013-03-14 |
2019-03-06 |
Galapagos NV |
Zielmoleküle und -verbindungen, und verfahren zur identifikation davon, zur behandlung von fibrotischen erkrankungen
|
CN105283439B
(zh)
|
2013-03-15 |
2018-02-02 |
英特瑞克斯顿股份有限公司 |
含硼的二酰基肼类化合物
|
WO2014193800A2
(en)
|
2013-05-28 |
2014-12-04 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
US11053291B2
(en)
|
2014-02-19 |
2021-07-06 |
University Of Florida Research Foundation, Incorporated |
Delivery of Nrf2 as therapy for protection against reactive oxygen species
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
CA3179824A1
(en)
|
2014-06-25 |
2015-12-30 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2015317862A1
(en)
|
2014-09-17 |
2017-04-06 |
Intrexon Corporation |
Boron-containing diacylhydrazine compounds
|
EP3270959A1
(de)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
TW201710503A
(zh)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
新穎多核苷酸、載體、醫藥組成物以及其用途
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2017062953A1
(en)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
PT3368507T
(pt)
|
2015-10-28 |
2023-02-07 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
WO2018089527A1
(en)
|
2016-11-09 |
2018-05-17 |
Intrexon Corporation |
Frataxin expression constructs
|
WO2018142280A2
(en)
|
2017-01-31 |
2018-08-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
EP3539975A1
(de)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Mikropeptide und verwendungen davon
|
CA3109209A1
(en)
|
2018-08-10 |
2020-02-13 |
Eutilex Co., Ltd. |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
MX2021008358A
(es)
|
2019-01-11 |
2021-09-30 |
Acuitas Therapeutics Inc |
Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
|
CA3132817A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Cd40l compositions and methods for tunable regulation
|
WO2021136808A1
(en)
*
|
2020-01-03 |
2021-07-08 |
Ascendis Pharma A/S |
Conjugates undergoing intramolecular rearrangements
|
KR20220139319A
(ko)
|
2020-01-08 |
2022-10-14 |
옵시디안 테라퓨틱스, 인크. |
조정 가능한 전사의 조절을 위한 조성물 및 방법
|
EP3885440A1
(de)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Spaltinteine und deren verwendungen
|
IL299787A
(en)
|
2020-07-16 |
2023-03-01 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
EP4448485A2
(de)
|
2021-12-16 |
2024-10-23 |
Acuitas Therapeutics, Inc. |
Lipide zur verwendung in lipidnanopartikelformulierungen
|